• Something wrong with this record ?

MUS81 cleaves TOP1-derived lesions and other DNA-protein cross-links

V. Marini, F. Nikulenkov, P. Samadder, S. Juul, BR. Knudsen, L. Krejci

. 2023 ; 21 (1) : 110. [pub] 20230516

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
206292/E/17/Z Wellcome Trust - United Kingdom

BACKGROUND: DNA-protein cross-links (DPCs) are one of the most deleterious DNA lesions, originating from various sources, including enzymatic activity. For instance, topoisomerases, which play a fundamental role in DNA metabolic processes such as replication and transcription, can be trapped and remain covalently bound to DNA in the presence of poisons or nearby DNA damage. Given the complexity of individual DPCs, numerous repair pathways have been described. The protein tyrosyl-DNA phosphodiesterase 1 (Tdp1) has been demonstrated to be responsible for removing topoisomerase 1 (Top1). Nevertheless, studies in budding yeast have indicated that alternative pathways involving Mus81, a structure-specific DNA endonuclease, could also remove Top1 and other DPCs. RESULTS: This study shows that MUS81 can efficiently cleave various DNA substrates modified by fluorescein, streptavidin or proteolytically processed topoisomerase. Furthermore, the inability of MUS81 to cleave substrates bearing native TOP1 suggests that TOP1 must be either dislodged or partially degraded prior to MUS81 cleavage. We demonstrated that MUS81 could cleave a model DPC in nuclear extracts and that depletion of TDP1 in MUS81-KO cells induces sensitivity to the TOP1 poison camptothecin (CPT) and affects cell proliferation. This sensitivity is only partially suppressed by TOP1 depletion, indicating that other DPCs might require the MUS81 activity for cell proliferation. CONCLUSIONS: Our data indicate that MUS81 and TDP1 play independent roles in the repair of CPT-induced lesions, thus representing new therapeutic targets for cancer cell sensitisation in combination with TOP1 inhibitors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011427
003      
CZ-PrNML
005      
20230801133033.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12915-023-01614-1 $2 doi
035    __
$a (PubMed)37194054
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Marini, Victoria $u Department of Biology, Masaryk University, Kamenice 5/B07, Brno, 62500, Czech Republic $u International Clinical Research Center, Center for Biomolecular and Cellular Engineering, St. Anne's University Hospital Brno, Pekařská 53, Brno, 60200, Czech Republic
245    10
$a MUS81 cleaves TOP1-derived lesions and other DNA-protein cross-links / $c V. Marini, F. Nikulenkov, P. Samadder, S. Juul, BR. Knudsen, L. Krejci
520    9_
$a BACKGROUND: DNA-protein cross-links (DPCs) are one of the most deleterious DNA lesions, originating from various sources, including enzymatic activity. For instance, topoisomerases, which play a fundamental role in DNA metabolic processes such as replication and transcription, can be trapped and remain covalently bound to DNA in the presence of poisons or nearby DNA damage. Given the complexity of individual DPCs, numerous repair pathways have been described. The protein tyrosyl-DNA phosphodiesterase 1 (Tdp1) has been demonstrated to be responsible for removing topoisomerase 1 (Top1). Nevertheless, studies in budding yeast have indicated that alternative pathways involving Mus81, a structure-specific DNA endonuclease, could also remove Top1 and other DPCs. RESULTS: This study shows that MUS81 can efficiently cleave various DNA substrates modified by fluorescein, streptavidin or proteolytically processed topoisomerase. Furthermore, the inability of MUS81 to cleave substrates bearing native TOP1 suggests that TOP1 must be either dislodged or partially degraded prior to MUS81 cleavage. We demonstrated that MUS81 could cleave a model DPC in nuclear extracts and that depletion of TDP1 in MUS81-KO cells induces sensitivity to the TOP1 poison camptothecin (CPT) and affects cell proliferation. This sensitivity is only partially suppressed by TOP1 depletion, indicating that other DPCs might require the MUS81 activity for cell proliferation. CONCLUSIONS: Our data indicate that MUS81 and TDP1 play independent roles in the repair of CPT-induced lesions, thus representing new therapeutic targets for cancer cell sensitisation in combination with TOP1 inhibitors.
650    _2
$a poškození DNA $7 D004249
650    _2
$a oprava DNA $7 D004260
650    12
$a fosfodiesterasy $x genetika $x metabolismus $7 D010727
650    _2
$a Saccharomyces cerevisiae $7 D012441
650    12
$a Saccharomyces cerevisiae - proteiny $x genetika $x metabolismus $7 D029701
650    _2
$a DNA-topoisomerasy I $x genetika $x metabolismus $7 D004264
650    12
$a DNA vazebné proteiny $x genetika $x metabolismus $7 D004268
650    12
$a endonukleasy $x genetika $x metabolismus $7 D004720
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nikulenkov, Fedor $u Department of Biology, Masaryk University, Kamenice 5/B07, Brno, 62500, Czech Republic
700    1_
$a Samadder, Pounami $u Department of Biology, Masaryk University, Kamenice 5/B07, Brno, 62500, Czech Republic
700    1_
$a Juul, Sissel $u Department of Molecular Biology and Genetics, Aarhus University, Universitetsbyen 81, Aarhus, 8000, Denmark
700    1_
$a Knudsen, Birgitta R $u Department of Molecular Biology and Genetics, Aarhus University, Universitetsbyen 81, Aarhus, 8000, Denmark
700    1_
$a Krejci, Lumir $u Department of Biology, Masaryk University, Kamenice 5/B07, Brno, 62500, Czech Republic. lkrejci@chemi.muni.cz $u International Clinical Research Center, Center for Biomolecular and Cellular Engineering, St. Anne's University Hospital Brno, Pekařská 53, Brno, 60200, Czech Republic. lkrejci@chemi.muni.cz $u National Centre for Biomolecular Research, Masaryk University, Kamenice 5/C04, Brno, 625 00, Czech Republic. lkrejci@chemi.muni.cz $1 https://orcid.org/0000000247321405 $7 xx0125663
773    0_
$w MED00008168 $t BMC biology $x 1741-7007 $g Roč. 21, č. 1 (2023), s. 110
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37194054 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133030 $b ABA008
999    __
$a ok $b bmc $g 1963689 $s 1197692
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 21 $c 1 $d 110 $e 20230516 $i 1741-7007 $m BMC biology $n BMC Biol $x MED00008168
GRA    __
$a 206292/E/17/Z $p Wellcome Trust $2 United Kingdom
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...